NewsRelease
PatentApplication Cites Cleanascite™ In Methods to Diagnose InsulinResistance
MONMOUTHJUNCTION, NJ,April3, 2019 -- BiotechSupport Group reports on a recent patent application describing thesimplicity and efficiency of their lipid clearance sample preparationtechnology for reducing analytical variables in liquid chromatographycoupled to mass spectrophotometric (LC-MS) analysis of insulin andC-peptide. The citation is:
Shiffman,Dov, et al. "Methodsfor quantitation of insulin and c-peptide."U.S. Patent Application No. 15/942,188.
Theinventors describe methods for diagnosing or prognosing insulinresistance in diabetic and pre-diabetic patients, the methodcomprising determining the amount of insulin and C-peptide in asample. Mass spectrometric methods are described for detecting andquantifying insulin and C-peptide in a biological sample utilizingenrichment and/or purification methods coupled with tandem massspectrometric or high resolution/high accuracy mass spectrometrictechniques. The application states “Insome embodiments, serum is delipidated prior to quantitation by massspectrometry. … In some embodiments, the delipidation reagent isCLEANASCITE”.
“Thispatent application justifies the value of Cleanascite™ as a serumdelipidation reagent so that better quantitative analysis of targetedprotein analytes can be monitored by LC-MS.” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
https://www.biotechsupportgroup.com/Articles.asp?ID=456
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com.
Contact:
MatthewKuruc
732-274-2866,
[email protected]